507
Participants
Start Date
February 28, 2002
Primary Completion Date
December 31, 2004
Study Completion Date
December 31, 2004
GW-1000-02
Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
Gartnavel General Hospital, Glasgow
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY